Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Alpha Cognition Inc (ACOG) and Fulcrum Therapeutics (FULC)

Tipranks - Thu Feb 26, 5:40AM CST

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alpha Cognition Inc (ACOGResearch Report) and Fulcrum Therapeutics (FULCResearch Report).

Claim 50% Off TipRanks Premium

Alpha Cognition Inc (ACOG)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Alpha Cognition Inc, with a price target of $18.00. The company’s shares closed last Tuesday at $6.01.

According to TipRanks.com, Selvaraju is a 5-star analyst with an average return of 23.3% and a 56.8% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Santhera Pharmaceuticals Holding, Reviva Pharmaceuticals Holdings, and Aardvark Therapeutics, Inc. ;'>

Currently, the analyst consensus on Alpha Cognition Inc is a Moderate Buy with an average price target of $18.00.

See today’s best-performing stocks on TipRanks >>

Fulcrum Therapeutics (FULC)

Bank of America Securities analyst Tazeen Ahmad reiterated a Sell rating on Fulcrum Therapeutics yesterday and set a price target of $7.00. The company’s shares closed last Tuesday at $8.58.

According to TipRanks.com, Ahmad is a 3-star analyst with an average return of 0.9% and a 54.7% success rate. Ahmad covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, KalVista Pharmaceuticals, and Apellis Pharmaceuticals. ;'>

Fulcrum Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $17.00.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.